Subscribe to Entrepreneur for $5
Subscribe

Big Week for FAANG, Economic Reads

The Dow is +25 points, the S&P 500 +5 and the tech-heavy Nasdaq, which houses the FAANG stocks, is +45 points at this hour.

By
This story originally appeared on Zacks

Monday, October 25, 2021



Much excitement comes to Wall Street this week, with calendar Q3 earnings reports expected from Facebook FB, Microsoft MSFT, Alphabet GOOGL and Apple AAPL, among others. We’re now deep in the heart of earnings season, and pre-market activity is cautiously optimistic: the Dow is +25 points, the S&P 500 +5 and the tech-heavy Nasdaq, which houses the FAANG stocks, is +45 points at this hour.



We also see a bevy of new economic prints this week, although there is nothing major on the docket for today. These include Case-Shiller home prices, Consumer Confidence, New Home Sales, Durable Goods, Q3 GDP, Personal Income/Consumer Spending and Jobless Claims. Combined with Q3 earnings reports, the Fed will be well equipped with information on which to decide monetary policy when its next meeting convenes next week.



Facebook will be the first of the FAANG stocks to report, after the closing bell today. Accompanying these numbers today are a series of media reports regarding internal dissent among company operatives, part of which we saw in the testimony of whistleblower Frances Haugen a couple weeks ago. Right now, the Zacks Rank #3 (Hold)-rated company is expected to bring in $3.20 per share on $29.55 billion in revenues.



Consumer staples major Kimberly-Clark KMB posted mix results this morning on its Q3 earnings, with $1.39 per share well off the $1.66 per share pace expected by analysts. This marks the third straight bottom-line miss for the parent of Huggies, Kleenex and many other commercial paper products. Revenues came in a hair above expectations, to $5.01 billion in the quarter.



In today’s pre-market, Kimberly-Clark shares are down -3% on this news. Partly this is due to a ratcheting down of full-year earnings expectations, now to a range of $6.05-6.25 per share. The Zacks consensus previously had been $6.65, so expect downgrades on the bottom line here, and perhaps a lowering of the Zacks Rank as a result.



Moderna MRNA has released a positive study regarding efficacy of its Covid vaccine in children 6-11 years of age. Two half-dose shots given four weeks apart was said to have given a favorable safety profile. An FDA submission is forthcoming. The FDA will hold a hearing this week on the Pfizer PFE/BioNTech BNTX clearance for use in children. Shares of Moderna are up modestly on the news, but down big over the past month.



Getting back to the markets, the S&P 500 so far is +5.5%, and on pace for its strongest full month since November 2020. The Dow, notching a new closing high Friday, is +5.4% for the month of October so far — its strongest performance since March of this year. This week’s FAANG stocks will articulate plenty of what’s going on at the Nasdaq, and whether that index may shoot for fresh all-time highs in the near future itself.



Questions or comments about this article and/or its author? Click here>>

- Zacks


Infrastructure Stock Boom to Sweep America

A massive push to rebuild the crumbling U.S. infrastructure will soon be underway. It’s bipartisan, urgent, and inevitable. Trillions will be spent. Fortunes will be made.

The only question is “Will you get into the right stocks early when their growth potential is greatest?”

Zacks has released a Special Report to help you do just that, and today it’s free. Discover 7 special companies that look to gain the most from construction and repair to roads, bridges, and buildings, plus cargo hauling and energy transformation on an almost unimaginable scale.

Download FREE: How to Profit from Trillions on Spending for Infrastructure >>



Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

 

Apple Inc. (AAPL): Free Stock Analysis Report

 

Microsoft Corporation (MSFT): Free Stock Analysis Report

 

Pfizer Inc. (PFE): Free Stock Analysis Report

 

KimberlyClark Corporation (KMB): Free Stock Analysis Report

 

Moderna, Inc. (MRNA): Free Stock Analysis Report

 

SPDR S&P 500 ETF (SPY): ETF Research Reports

 

Facebook, Inc. (FB): Free Stock Analysis Report

 

Alphabet Inc. (GOOGL): Free Stock Analysis Report

 

BioNTech SE Sponsored ADR (BNTX): Free Stock Analysis Report

 

To read this article on Zacks.com click here.

 

Zacks Investment Research

 

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report